메뉴 건너뛰기




Volumn 56, Issue 9, 2009, Pages 1095-1101

Investigation into the efficacy and safety of octreotide LAR in japanese patients with acromegaly: Shizuoka study

Author keywords

Acromegaly; GH; Insulin like growth factor 1; Octreotide

Indexed keywords

CABERGOLINE; GROWTH HORMONE; HEMOGLOBIN A1C; NATEGLINIDE; OCTREOTIDE; SOMATOMEDIN C; SULFONYLUREA;

EID: 74749087245     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K09E-172     Document Type: Article
Times cited : (10)

References (23)
  • 1
    • 33845491265 scopus 로고    scopus 로고
    • Medical progress: Acromegaly
    • Melmed S (2006) Medical progress: Acromegaly. N Engl J Med 355: 2558-2573.
    • (2006) N Engl J Med , vol.355 , pp. 2558-2573
    • Melmed, S.1
  • 3
    • 49249113074 scopus 로고    scopus 로고
    • A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
    • Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93: 2957-2968.
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 2957-2968
    • Murray, R.D.1    Melmed, S.2
  • 4
  • 7
    • 49649113676 scopus 로고    scopus 로고
    • High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels
    • Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69: 432-435.
    • (2008) Clin Endocrinol (Oxf) , vol.69 , pp. 432-435
    • Schneider, H.J.1    Sievers, C.2    Saller, B.3    Wittchen, H.U.4    Stalla, G.K.5
  • 11
    • 0030740018 scopus 로고    scopus 로고
    • Cabergoline treatment of acromegaly: A preliminary dose finding study
    • Jackson SN, Fowler J, Howlett TA (1997) Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf) 46: 745-749.
    • (1997) Clin Endocrinol (Oxf) , vol.46 , pp. 745-749
    • Jackson, S.N.1    Fowler, J.2    Howlett, T.A.3
  • 12
    • 85137137537 scopus 로고    scopus 로고
    • Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171-1177.
    • Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171-1177.
  • 13
    • 0031812096 scopus 로고    scopus 로고
    • Stereotactic radiosurgery for recurrent surgically treated acromegaly: Comparison with fractionated radiotherapy
    • Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G (1998) Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 88: 1002-1008.
    • (1998) J Neurosurg , vol.88 , pp. 1002-1008
    • Landolt, A.M.1    Haller, D.2    Lomax, N.3    Scheib, S.4    Schubiger, O.5    Siegfried, J.6    Wellis, G.7
  • 14
    • 33645009542 scopus 로고    scopus 로고
    • Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: Predictors of tumor shrinkage
    • Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T (2006) Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage. Endocr J 53: 125-132.
    • (2006) Endocr J , vol.53 , pp. 125-132
    • Oshino, S.1    Saitoh, Y.2    Kasayama, S.3    Arita, N.4    Ohnishi, T.5    Kohara, H.6    Izumoto, S.7    Yoshimine, T.8
  • 15
    • 36549040940 scopus 로고    scopus 로고
    • Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly
    • Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2007) Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157: 579-587.
    • (2007) Eur J Endocrinol , vol.157 , pp. 579-587
    • Colao, A.1    Pivonello, R.2    Auriemma, R.S.3    Galdiero, M.4    Savastano, S.5    Lombardi, G.6
  • 17
    • 34347380169 scopus 로고    scopus 로고
    • A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
    • Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66: 859-868.
    • (2007) Clin Endocrinol (Oxf) , vol.66 , pp. 859-868
    • Mercado, M.1    Borges, F.2    Bouterfa, H.3    Chang, T.C.4    Chervin, A.5    Farrall, A.J.6    Patocs, A.7    Petersenn, S.8    Podoba, J.9    Safari, M.10    Wardlaw, J.11
  • 18
    • 45149134343 scopus 로고    scopus 로고
    • No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly
    • Colao A, Marek J, Goth MI, Caron P, Kuhn JM, Minuto FM, Weissman NJ (2008) No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab 93: 2243-2248.
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 2243-2248
    • Colao, A.1    Marek, J.2    Goth, M.I.3    Caron, P.4    Kuhn, J.M.5    Minuto, F.M.6    Weissman, N.J.7
  • 19
    • 20844461864 scopus 로고    scopus 로고
    • Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: The relationship with endogenous srif activity and response to octreotide
    • Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 51: 227-236.
    • (2004) Endocr J , vol.51 , pp. 227-236
    • Park, C.1    Yang, I.2    Woo, J.3    Kim, S.4    Kim, J.5    Kim, Y.6    Sohn, S.7    Kim, E.8    Lee, M.9    Park, H.10    Jung, J.11    Park, S.12
  • 22
    • 0023023461 scopus 로고
    • Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly
    • Horikawa R, Takano K, Hizuka N, Asakawa K, Shibasaki T, Masuda A, Shizume K (1986) Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly. Endocrinol Jpn 33: 743-749.
    • (1986) Endocrinol Jpn , vol.33 , pp. 743-749
    • Horikawa, R.1    Takano, K.2    Hizuka, N.3    Asakawa, K.4    Shibasaki, T.5    Masuda, A.6    Shizume, K.7
  • 23
    • 0029586762 scopus 로고
    • Short-term effects of octreotide on glucose tolerance in patients with acromegaly
    • Sato K, Takamatsu K, Hashimoto K (1995) Short-term effects of octreotide on glucose tolerance in patients with acromegaly. Endocr J 42: 739-745.
    • (1995) Endocr J , vol.42 , pp. 739-745
    • Sato, K.1    Takamatsu, K.2    Hashimoto, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.